Pharma major Dr Reddys Laboratories has received US Food and Drug Administration (FDA) approval for Azacitidine Injection 100 mg/vial, a bioequivalent generic version of VIDAZA (azacitidine for injection) on September 16, 2013. The launch of product in the market is planned in the near-term.
The VIDAZA brand had U.S. sales of approximately $378.5 Million for the most recent twelve months ending July 2013 according to IMS Health.
Dr Reddy's Azacitidine for Injection 100 mg/vial is available in single use-vials.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1879.00 |
| Dr. Reddys Labs. | 1354.35 |
| Cipla | 1463.80 |
| Zydus Lifesciences | 1115.15 |
| Lupin | 2408.00 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: